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Effect of Alpha-adrenergic Blockade and 
Anticholinergic Agents on the 
Decentralized Primate Bladder 
Edward J. McGuire and Joan A. Savastano 
Department of Urology, University Hospital, University of Michigan, Ann Arbor, Michigan 
The effect of anticholinergic and alpha-adrenergic blocking agents on the primate bladder 
decentralized at the sacral level was studied. Both agents diminish the intravesical pressure 
response to filling and slightly increase capacity. Each appears to exert an independent 
effect. 
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INTRODUCTION 
A corrective effect of alpha-adrenergic blocking agents on ureteral dilatation 
has been reported [Stockamp, 1975; Stockamp and Schreiter, 19731. While this effect 
could be related to decreased bladder outlet resistance, there are circumstances where 
that seems unlikely to be the explanation. The preganglionically denervated bladder 
which coexists with a nonfunctional internal but active skeletal sphincter encounters 
urethral resistance in the area of the pelvic diaphragm, an area not influenced by 
alpha blockade [McGuire et al, 1981; McGuire, 19771. 
Sundin and Dahlstrom [1973] and Sundin and co-workers [1977] reported an 
increase in alpha-adrenergic receptor sites in the decentralized cat and human detrusor 
and a change from the predominance of beta-adrenergic (relaxation) function to a 
predominance of alpha-adrenergic (contraction) function during bladder filling. The 
decreased bladder compliance which develops after sacral level decentralization may 
thus be partially an alpha-adrenergic-receptor-mediated influence. That portion of 
decreased compliance related to alpha-adrenergic receptor activity should be blocked 
by phenoxybenzamine, and a possible portion due to cholinergic influences should be 
blocked by anticholinergic agents. To study these relationships, seven female crabeat- 
er monkeys (weight 26-52 kg) were evaluated urodynamically before and at 6 weeks 
after intradural rhizotomy performed from L5 through S4. 
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Fig. 1. Urethral pressure profilometry in decentralized monkey measuring 21 cm of water in the 
proximal 1-2 cm of urethra (C) with superimposed repeat profilometry after the administration of 2 mg 
of phenoxybenzarnine (Pb) intravenously, demonstrating a decrease in urethral closing pressure to less 
than 6 cm of water. 
NEUROSURGICAL METHODS 
After Ketaset sedation, general endotracheal anesthesia was induced with halo- 
thane and 0, and a lumbosacral laminectomy was performed. The fifth lumbar 
through fourth sacral roots were divided within the dural canal with the aid of an 
operating microscope. All of the roots were completely sectioned. Following opera- 
tion, the monkeys were managed by Crede voiding on a b.i.d. basis. 
URODYNAMIC METHODS 
Under Ketaset sedation, urethral closing pressure profiles were performed using 
a 5 French feeding tube with a single lateral perfusion aperture. The urethral catheter 
was perfused with a Harvard syringe pump at 2 ml per minute. Cystometrograms 
were performed via an 8 French Foley catheter with ,a 3-cc balloon inflated to occlude 
the bladder outlet. Bladder filling was induced with a Harvard syringe pump at 6 ml 
per minute. Intravesical pressures and urethral closing pressure profiles were mea- 
sured via a side-arm tube, a P23A Statham pressure transducer, and recorded on a 
Grass polygraph. Transvaginal placement of two #30 Grass monopolar needle elec- 
trodes was used to measure urethral sphincter EMG activity. 
RESULTS 
Urodynamic evaluations performed 6 weeks aftcr rhizotomy revealed no skeletal 
sphincter activity as determined by EMG recordings with residual smooth-muscle 
closure of the proximal urethra measuring a peak of 20 (1 +_5) cm of water (Fig. 1). 
Cystometrograms performed via a Foley catheter showed hypertonic areflexic bladder 
pressure filling curves (Fig. 2). Administration of phenoxybenzamine (2 mg intrave- 
nously) flattened the intravesical pressure response to filling and increased capacity 
slightly. At capacity, a sharp rise in intravesical pressure occurred in the control and 
the phenoxybenzamine-treated animals (Fig. 2). Urethral pressure profiles performed 
subsequent to phenoxybenzamine injection showed a marked decrease in peak urethral 
closing pressure (Fig. 1). 
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Fig. 2. Recordings of intravesical pressure response to bladder filling at 20 ml/min in decentralized 
monkey. Control studies show a continuous rise in bladder pressure with filling reaching 40 cm of water 
at a 60-ml bladder volume. The administration of phenoxybenzamine (Pb) (2 mg intravenously) results 
in a bladder pressure curve that remains at less than 20 cm of water until a bladder volume of 100 cc is 
reached, at which time intravesical pressure rises sharply. After the administration of phenoxybenzamine 
(Pb) (2 mg intravenously) and atropine (.25 mg intravenously), intravesical pressure remains below 20 
cm of water to a bladder volume of 100 ml when bladder pressure rises sharply. 
The administration of both phenoxybenzamine and atropine (.25 mg intrave- 
nously) prolonged the low pressure vesical response to filling and increased capacity 
as compared to the findings of those animals treated with phenoxybenzamine alone or 
the control situation (Fig. 2). Depression in the intravesical pressure response to 
filling up to capacity was more marked when both drugs were used concurrently. 
DISCUSSION 
In a prior report we described the evolution of neurogenic vesical dysfunction 
after experimental sacral rhizotomy with resultant partial vesical decentralization 
[McGuire et al, 19821. The changes include a loss of skeletal sphincter activity and 
the gradual development of a hypertonic bladder. While vesical capacity after decen- 
tralization is greater than in normal animals, or those with suprasacral spinal cord 
injury, intravesical pressures for a given volume are higher. 
In the female monkeys studied here, vesical wall thickening and trabeculation 
occurred universally, but upper tract deterioration at least by gross examination of the 
ureters did not. This appears to be related to low urethral resistance with a peak 
pressure of 20 cm of water in these animals. Occlusion of the vesical outlet with a 
Foley catheter permits assessment of the intravesical pressure response to filling and 
obviates the influence of alpha-adrenergic blocking agents on urethral closing pressure 
exerted by smooth musculature. In this circumstance, both phenoxybenzamine and 
atropine when given separately diminished the intravesical pressure response to filling 
and increased bladder capacity. When both agents were given together, a more 
pronounced shift of the pressure volume curve to the right occurred. 
The relationship between intravesical pressure and ureteral resistance to perf%- 
sion has been shown clinically and experimentally [McGuire et al, 1981; Coolsaet et 
al, 19821. Intravesical pressure has a direct parallel effect on ureteral resistance which 
is particularly noticeable after decentralization, since the bladder pressure rise with 
filling is steady and progressive. Adverse ureteral effects are seen clinically if the 
“denervated” bladder must achieve a pressure of 40 cm of water or more to induce 
urethral urinary flow. To protect the ureters from intravesical pressure, intermittent 
catheterization can be combined with anticholinergic agents which have a direct effect 
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on bladder “tone. ” Alpha-adrenergic blockade could diminish vesical pressure with 
filling by two possible modes of action. Alpha-adrenergic blockade diminishes ure- 
thral resistance and could lead to urethral urinary loss at a lower bladder pressure, 
provided the “external sphincter” were nonfunctional. In addition, phenoxybenza- 
mine appears to diminish intrinsic vesical tone after decentralization. The net effect 
of administration of either phenoxybenzamine or atropine was a decrease in intraves- 
ical pressure at a given volume until capacity was reached, at which time bladder 
pressure rose steeply. It appears that vesical capacity is partly limited by the visco- 
elastic properties of the bladder wall, but that either or both of these agents have an 
effect on intrinsic detrusor tone. Our results suggest that the portion of intravesical 
pressure which is influenced by these drugs is the result of a neuromuscular process, 
and not simply collagen deposition and mural fibrosis. Clinically, a decentralized 
bladder fills and gains pressure until urethral resistance is overcome and urinary loss 
occurs. There are two problems with this kind of lower urinary tract dysfunction: 
incontinence and an adverse effect on ureteral function. Since intravesical pressure is 
related to volume, simply decreasing urethral resistance which allows urine flow at a 
lower volume can reduce ureteral dilatation. This, of course, makes incontinence 
worse. Alternatively, this kind of dysfunction may be treated by intermittent cathet- 
erization, in which case it is important to diminish intravesical pressure as much as 
possible to prevent incontinence, as well as to prevent adverse effects on ureteral 
function. It seems likely that alpha-adrenergic blockade in those individuals with only 
a functional internal sphincter, and no skeletal sphincter function, might well aggra- 
vate incontinence due to its effect on the smooth sphincter. In the typical myelodys- 
plastic patient with no internal sphincter function, and a relatively high pressure 
skeletal sphincter, any method to decrease intravesical pressure and facilitate storage 
would be helpful both for continence and to protect the ureters. Alpha-adrenergic 
blockade would not further influence urethral resistance. In those patients with 
areflexic vesical dysfunction selected for an artificial sphincter, both alpha-adrenergic 
blockade and anticholinergic therapy may be useful to diminish vesical pressure 
responses to filling, as well as to diminish intrinsic outlet resistance. 
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